Byondis B.V.
Nijmegen - Gelderland
www.byondis.com
Naam
Byondis B.V.
Website
www.byondis.com
Sector
Biotechnologisch speur- en ontwikkelingswerk voor overige toepassingen
Werkenden
100-499 wn.
Adres
Microweg 22
Postcode
6545CM
Plaatsnaam
Nijmegen
1 16 19 2 2025 24 3 a ability about accelerat adc addres advanc advances affected against aim all allow and announced antibodies/adcs antibody antibody-based antibody-drug appointment are art as asset at axis based best best-in-clas block breaking breakthrough bring broad busines by byon4228 byon4413 byondis cancer candidates capabilities carer cd123 cd47 cd47-sirpα cell checkpoint chief christoph clas clinical clos commercial condition conjugat conjugates contact control cookie currently cytotoxic d dedicated deliver destruction develop development direction discovery diversity dokter dos drug duba efficiency efficiently effort enabl enhanced enroll escalation escap eu exist expansion experienced exploit expressed facilities fda featured follow for from full fully fully-integrated futur general generation get gmp he hear hem hematological highly hom hous how humanized igg1 immun immune-stimulat immunology important in-hous includ includes index indication inhibitor innovativ inspected/approved integrated investor know korpus larg large-scal lead learn leverag limitation linkedin linker linker-drug lives mab malignancies management manufactur masked mba meaningful media moa moas modalities monoclonal mor multi multi-specific myeloid ned new novel officer on oncology optimiz optimized our overexpressed owned patient payload phd pioner pipelin pivotal platform play policies positioned potentially pre pre-clinical precision preclinical privacy production program promis proprietary purchas quality r rang read recognition research responsibl robust rol scal scienc scientific seamles selectivity ses sirpα solution specific sped stag stat state-of-the-art statement stimulat stories supply system target team technologies technology term that the therapeutic therapies thos through to today transform transformativ treatment trial tumor types ultimately undisclosed unique uniquely unmet us use utiliz validated various video view we weaknesses what which who wholly wholly-owned
Vind meer informatie over Byondis B.V. in de interactieve versie